A clinicopathological study of giant cell tumor of small bones

Yanagisawa, Michiro; Okada, Kyoji; Tajino, Takahiro; Torigoe, Tomoaki; Kawai, Akira; Nishida, Jun

doi:10.3109/03009734.2011.596290

Cited by 25 publications

(33 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…distal radius, proximal femur, axial skeleton, or small bone involvement, others have suggested that there are no relationships at all [4,5,7,9,14,19,21,22]. Cases involving the axial skeleton have been reported to have a particularly high recurrence rate [5].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of p53 protein expression in giant cell tumor of bone

Yalçinkaya

Uğraş²,

Kabul³

et al. 2015

pjp

View full text Add to dashboard Cite

Giant cell tumor of bone (GCTB) is a benign tumor with a tendency for local recurrence. GCTB may cause lung metastases, and secondary malignant GCTB is rare. Its histological appearance does not predict local aggressiveness and/or the metastatic potential of the tumor. We aimed to investigate the prognostic value of the Ki-67 proliferative index and p53 protein expression in GCTB in predicting local recurrence, lung metastasis, and malignant transformation. We retrospectively reviewed 42 cases of GCTB. The p53 expression was positive in 20 cases. We used 10% as a cut-off value for p53 expression. In 10 cases, there were local recurrences. Lung metastases were found in three cases and malignant transformation was found in one case with classical GCTB located in the sacrum three years following diagnosis. The Ki-67 index was higher in cases with recurrence, but this difference was not statistically significant. Of the recurrent cases, two had no p53 staining while eight had moderate-to-strong staining. The staining was usually weakly positive in the non-recurrent cases. In conclusion, we believe that p53 may be used as a marker for the biological behavior of GCTB.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of p53 protein expression in giant cell tumor of bone

Yalçinkaya

Uğraş²,

Kabul³

et al. 2015

pjp

View full text Add to dashboard Cite

show abstract

“…Based on both previous findings and current experience, it is hypothetically possible that tumor volume may also influence recurrence of primary GCTs. Logically, both PMMA cementation and bone graft treatments are likely to be less effective following intralesional curettage in cases of very small tumors, which are more difficult to excise and fill [31]. Because this raises the likelihood that some tumor cells will elude the hypothetical thermal effects of PMMA, such adjuvant treatment is likely to be less effective in GCTs with very small volumes.…”

Section: Discussionmentioning

confidence: 99%

Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis

et al. 2013

View full text Add to dashboard Cite

BackgroundReports of recurrence following restructuring of primary giant cell tumor (GCT) defects using polymethyl methacrylate (PMMA) bone cementation or allogeneic bone graft with and without adjuvants for intralesional curettage vary widely. Systematic review and meta-analysis were conducted to investigate efficacy of PMMA bone cementation and allogeneic bone grafting following intralesional curettage for GCT.MethodsMedline, EMBASE, Google Scholar, and Cochrane databases were searched for studies reporting GCT of bone treatment with PMMA cementation and/or bone grafting with or without adjuvant therapy following intralesional curettage of primary GCTs. Pooled risk ratios and 95% confidence intervals (CIs) for local recurrence risks were calculated by fixed-effects methods.ResultsOf 1,690 relevant titles, 6 eligible studies (1,293 patients) spanning March 2008 to December 2011 were identified in published data. Treatment outcomes of PMMA-only (n = 374), bone graft-only (n = 436), PMMA with or without adjuvant (PMMA + adjuvant; n = 594), and bone graft filling with or without adjuvant (bone graft + adjuvant; n = 699) were compared. Bone graft-only patients exhibited higher recurrence rates than PMMA-treated patients (RR 2.09, 95% CI (1.64, 2.66), Overall effect: Z = 6.00; P <0.001), and bone graft + adjuvant patients exhibited higher recurrence rates than PMMA + adjuvant patients (RR 1.66, 95% CI (1.21, 2.28), Overall effect: Z = 3.15, P = 0.002).ConclusionsLocal recurrence was minimal in PMMA cementation patients, suggesting that PMMA is preferable for routine clinical restructuring in eligible GCT patients. Relationships between tumor characteristics, other modern adjuvants, and recurrence require further exploration.

show abstract

“…As p63 immunostaining is positive only for the mononuclear cells in GCT, it may be indicative of the nature of individual tumors. In the study of GCT of small bones, p63 was found to be highly expressed in a case with two episodes of recurrence (7). This finding led us to consider the usefulness of p63 as a prognostic marker.…”

Section: Discussionmentioning

confidence: 99%

“…While there is controversy about the usefulness of p63 as a diagnostic marker for GCT, p63 has recently been identified to be highly expressed in this disease (4-6). In addition, in a clinicopathological study of GCT in small bones, p63 was found to be highly expressed in the case of a patient with two episodes of local recurrence, suggesting that p63 expression indicates GCT recurrence (7). The purpose of this study was to investigate retrospectively whether p63 is useful for the differential diagnosis of GCT or for the prediction of aggressiveness and risk of local GCT recurrence.…”

Section: Introductionmentioning

confidence: 99%

p63 as a prognostic marker for giant cell tumor of bone

Yanagisawa

Kakizaki

Okada

et al. 2012

Upsala Journal of Medical Sciences

Self Cite

View full text Add to dashboard Cite

Background and purposeGiant cell tumor of bone (GCT) is sometimes difficult to distinguish from other giant-cell-rich tumors such as chondroblastoma (CHB) and aneurysmal bone cyst (ABC). The usefulness of p63 as a diagnostic marker for GCT is controversial. While there have been no reports about p63 as a prognostic marker for local recurrence, various p63-positive rates in GCT have been reported. The purpose of this study was to investigate retrospectively whether p63 is useful as a diagnostic marker and/or a prognostic marker for local recurrence of GCT.MethodsThis study included 36 patients diagnosed with either GCT (n = 16), CHB (n = 9), ABC (n = 7), or non-ossifying fibroma (NOF) (n = 4). p63 immunostaining was performed for all specimens. The mean p63-positive rate was compared with the four diseases and between the recurrent and non-recurrent cases of GCT.ResultsAlthough the mean p63-positive rate for GCT (36.3%) was statistically higher than that of all other diseases examined (CHB: 15.2%; ABC: 5.8%; NOF: 3.4%), p63 was not specific for GCT. The mean p63-positive rate for recurrent GCT cases (73.6%) was statistically higher than that for non-recurrent cases (29.1%).ConclusionIn the diagnosis of GCT, p63 is a useful but not a conclusive marker. However, p63 did appear to indicate the biological aggressiveness of GCT. Therefore, p63 may help surgeons to estimate the risk of recurrence after surgery and help them to choose the best treatment for each GCT case.

show abstract

A clinicopathological study of giant cell tumor of small bones

Cited by 25 publications

References 10 publications

Prognostic value of p53 protein expression in giant cell tumor of bone

Prognostic value of p53 protein expression in giant cell tumor of bone

Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis

p63 as a prognostic marker for giant cell tumor of bone

Contact Info

Product

Resources

About